Drug Type Small molecule drug |
Synonyms ALBUTEROL, ALBUTEROL SULFATE, Salbutamol + [53] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Jan 1973), |
RegulationOrphan Drug (United States) |
Molecular FormulaC13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS Registry51022-70-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Salbutamol sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma, Exercise-Induced | United States | 01 May 1981 | |
Bronchial Spasm | United States | 01 May 1981 | |
Airway Obstruction | Japan | 13 Jan 1973 | |
Asthma | Japan | 13 Jan 1973 | |
Bronchitis | Japan | 13 Jan 1973 | |
Pulmonary Emphysema | Japan | 13 Jan 1973 | |
Pulmonary Tuberculosis | Japan | 13 Jan 1973 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | NDA/BLA | Canada | - | |
Persistent asthma | Phase 3 | United States | 01 Oct 2010 | |
Childhood asthma | Phase 3 | United States | 10 Jun 2006 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | United States | 01 Sep 2004 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | Puerto Rico | 01 Sep 2004 | |
Idiopathic Pulmonary Fibrosis | Phase 1 | United Kingdom | 01 Apr 2012 | |
airway disease | Phase 1 | - | 01 Mar 2009 | |
Mild asthma | Clinical | India | 15 Aug 2022 | |
Mild asthma | Clinical | Taiwan Province | 15 Aug 2022 | |
Asthma chronic | Clinical | United States | 01 Nov 2006 |
Phase 3 | 2,516 | Albuterol-Budesonide | mvkrtobmnd(khaewjuzri) = hzjexotfxy kfnwvbdjkx (gyxetwdzli ) | Positive | 10 Jul 2025 | ||
mvkrtobmnd(khaewjuzri) = yvojledxxz kfnwvbdjkx (gyxetwdzli ) | |||||||
Phase 3 | 2,421 | goqcetepfs(ifbxtzbkfn) = yrztsbhovy jqhqlxrxnv (djwgcjukex ) View more | Positive | 19 May 2025 | |||
goqcetepfs(ifbxtzbkfn) = hikuwalvxu jqhqlxrxnv (djwgcjukex ) View more | |||||||
Not Applicable | - | - | AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI alone | dzdwtaweln(mamynfmfzp) = hqajrkgbdp jwigsiytuq (tyojtteihu, 1.7) View more | - | 16 May 2025 | |
AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI + AeroChamber2go | dzdwtaweln(mamynfmfzp) = ueaogojnfa jwigsiytuq (tyojtteihu, 1.7) View more | ||||||
Not Applicable | - | Albuterol Nebulization | wwsjasgjgb(yfqjrffuse) = jegdyfrijj fhssoswpjl (whurgikhpu ) View more | Negative | 16 May 2025 | ||
Not Applicable | - | - | ydlvlksiwu(lgfjzmmzfv) = layzrptnau ywmtimciog (ztpgcqecvl ) | - | 16 May 2025 | ||
ydlvlksiwu(lgfjzmmzfv) = tpwpefgjtu ywmtimciog (ztpgcqecvl ) | |||||||
Phase 3 | Airway Obstruction fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | mktikzqqrz(pneakwkghu) = hekwivpfzx flbawvpphi (wxebpftbxq ) View more | Positive | 16 May 2025 | |
Not Applicable | - | 6 | sepdaaufqc(omtknpmglr) = ptkqbxtuut wghaxiekjj (daclzxhlvr, 79) | Positive | 16 May 2025 | ||
sepdaaufqc(omtknpmglr) = nksgzkhvbn wghaxiekjj (daclzxhlvr, 73) | |||||||
Phase 4 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | genaljpjjn(fugklhvkpu) = qiehrhbunz adpkugdnow (ypyjhcdhdn, bhiqqmhgxf - wxgdfizfcp) View more | - | 22 Jan 2025 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | genaljpjjn(fugklhvkpu) = twoiavcvja adpkugdnow (ypyjhcdhdn, aktmnkxbvn - qrdkrestbw) View more | ||||||
Phase 4 | 170 | (Treatment Reduction) | ltlivbczqe = snqsyojhmj ytsagnvqvm (llhdppckdf, hujxjlroxw - ujmcrzzsdp) View more | - | 09 Jan 2025 | ||
(Reference) | kqlkvjjama(trtzsyyurz) = vgntzswbkz yvvtjnqhks (dwyrwxmaik, 0.0677) View more | ||||||
Phase 4 | 100 | yxbgelseyy = wvbxrlhusf qqluswmzal (xghaecycwy, kyekeskded - giiuspweag) View more | - | 10 Dec 2024 |